Novogen (NASDAQ:KZIA) Coverage Initiated by Analysts at BTIG Research

BTIG Research initiated coverage on shares of Novogen (NASDAQ:KZIA) in a research report issued to clients and investors on Wednesday,Benzinga reports. The firm set a “buy” rating and a $34.00 price target on the stock. BTIG Research’s price objective points to a potential upside of 141.48% from the stock’s previous close.

A number of other equities analysts also recently issued reports on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Novogen in a research report on Tuesday, April 21st. Lake Street Capital assumed coverage on shares of Novogen in a research report on Thursday, June 11th. They set a “buy” rating and a $32.00 target price for the company. Wall Street Zen downgraded shares of Novogen from a “buy” rating to a “hold” rating in a research report on Sunday, March 8th. Finally, Laidlaw started coverage on shares of Novogen in a research report on Wednesday, April 15th. They issued a “buy” rating and a $25.00 price target on the stock. Five investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $25.80.

Novogen Trading Down 2.6%

Shares of NASDAQ:KZIA opened at $14.08 on Wednesday. Novogen has a 52 week low of $4.86 and a 52 week high of $17.40. The firm’s fifty day moving average is $12.96 and its 200-day moving average is $9.46.

Novogen (NASDAQ:KZIA) last posted its quarterly earnings data on Saturday, February 14th. The company reported ($1.34) earnings per share for the quarter. The company had revenue of $4.89 million during the quarter. As a group, equities analysts expect that Novogen will post -0.01 earnings per share for the current fiscal year.

About Novogen

Novogen (NASDAQ:KZIA) is a clinical-stage biotechnology company focused on the discovery and development of novel small-molecule therapeutics for the treatment of cancer. The company’s pipeline includes GDC-0084, a brain-penetrant phosphoinositide 3-kinase (PI3K) inhibitor in Phase II development for glioblastoma, as well as Cantrixil, an orally bioavailable small molecule designed to target treatment-resistant ovarian cancer stem cells. Novogen’s research efforts leverage structure-based drug design to optimize selectivity and pharmacokinetic profiles, seeking to address high-unmet medical needs in oncology.

Founded in Australia and now headquartered in New York City, Novogen maintains research facilities in Perth and collaborates with academic institutions and contract research organizations worldwide.